The identification of functional non-coding mutations is a key challenge in the field of genomics, where whole-genome re-sequencing can swiftly generate a set of all genomic variants in a sample, such as a tumor biopsy. The size of the human regulatory landscape places a challenge on finding recurrent cis-regulatory mutations across samples of the same cancer type. Therefore, powerful computational approaches are required to sift through the tens of thousands of noncoding variants, to identify potentially functional variants that have an impact on the gene expression profile of the sample. Here we introduce an integrative analysis pipeline, called µ-cisTarget, to filter, annotate and prioritize non-coding variants based on their putative effect on the underlying 'personal' gene regulatory network. We first validate µ-cisTarget by re-analyzing three cases of oncogenic non-coding mutations, namely the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma. Next, we re-sequenced the full genome of ten cancer cell lines of six different cancer types, and used matched transcriptome data and motif discovery to infer master regulators for each sample. We identified candidate functional non-coding mutations that generate de novo binding sites for these master regulators, and that result in the up-regulation of nearby oncogenic drivers. We finally validated the predictions using tertiary data including matched epigenome data. Our approach is generally applicable to resequenced cancer genomes, or other genomes, when a disease-or sample-specific gene signature is available for network inference. µ-cisTarget is available from http://mucistarget.aertslab.org.
Introduction
Oncogenic programs are characterized by aberrant gene expression profiles. A gene regulatory network underlying a cancer transcriptome can be considered as a perturbed stable network configuration, or as a cancer attractor state [1] . Gene expression changes leading from a normal cell to a malignant state are generally due to a series of acquired somatic mutations, which often affect proteins playing a key role in transcriptional regulation [2] . These can include mutations, amplifications, or translocations leading to an altered function or expression of transcription factors (e.g., MYC, TAL1, MITF, TP53), co-factors (EZH2, RB1, IDH1, MLL), or signalling molecules that lead to downstream alterations in transcription factor activity (e.g., RAS/RAC/RAF, KIT, PTEN, CDKN2A). More subtle changes can also occur in gene regulatory networks, which may cause fine-tuning of the emerging transcriptome rather than necessarily yielding a different attractor state. Such local network changes can involve the addition or removal of an edge in the network, affecting a single interaction between a transcription factor and a target gene. Edge perturbations can be caused by a mutation of a transcription factor binding site in a promoter or enhancer, leading to a de novo gain, or a loss, of the binding site, and a consequential expression change of a nearby target gene. Several examples of such perturbations are known to be associated to oncogenic programs, such as the gain of an ETSfamily binding site in the TERT promoter, the gain of a MYB binding site in a 7.5 kb upstream TAL1 enhancer [3] [4] [5] , and the recently identified gain of a MYB binding site 4 kb upstream of LMO1 oncogene [6] . Note that whereas these three examples occur recurrently across melanoma or liver cancer (for TERT) or across T-cell acute lymphoblastic leukemia (for TAL1 and LMO1), they represent exceptional cases, since whole-genome sequencing, even across large cohorts such as 560 breast cancer genomes [7] failed to identify additional binding site changes that are significantly recurrent [8] (see also recent reviews [9] [10] [11] ). This suggests either that cis-acting mutations are usually passenger mutations rather than driver mutations, or that they can occur as drivers at diverse positions, spread across hundreds of kilobases affecting the regulation of a target gene. The latter would render current cohort sizes underpowered, and would require different approaches to identify causal cis-regulatory mutations and their downstream consequences.
Computational predictions of a gain or loss of a transcription factor binding site can be performed by scoring the reference and mutated sequence with a position weight matrix (PWM) of the candidate factor [12, 13] . This results in a "delta" PWM score, to which an arbitrary threshold can be applied to decide whether the gain or loss is strong enough. Such an approach is implemented 3 in various bioinformatics tools, such as FunSeq2 [14] and OncoCis [15] . However, as position weight matrices are notorious in producing false positive predictions, also the delta score results in an excess of false positive gains or losses of binding sites. A possible solution to this problem is to take the context of the binding site into account, thus the encompassing regulatory region (promoter or enhancer). For example, the gain of MYB binding site in a random genomic position may not lead to de novo enhancer activity, whereas such a gain in the context of RUNX binding sites (MYB and RUNX bind together to leukemia enhancers) may cause ectopic enhancer activity [16] . Computationally, this solution depends on training more complex enhancer models, for example based on k-mer SVMs [17] , Random Forests [16] , or deep learning (deepSEA [18] ). The main limitation of this approach is the dependence on high-quality training data to construct accurate enhancer models [16] .
Here we investigate how "personalised" gene regulatory network reconstruction can be used to identify specific candidate cis-regulatory driver mutations in cancer genomes. Gene regulatory network inference is a common technique that has provided insight into master regulators in many cancer types [19] [20] [21] , and the targets they regulate. Here, we exploit gene regulatory networks for the prioritization of non-coding mutations. Particularly, by first identifying the master regulators operating in cancer sample, we can identify those non-coding mutations that generate de novo targets of these master regulators. We develop an online tool to streamline this process, called µ-cisTarget, and we demonstrate the use of µ-cisTarget on known cases of TERT promoter and TAL1 enhancer mutations. Finally, we predict new cis-regulatory mutations in ten cancer cell lines for which we sequenced the genome, transcriptome, and epigenome.
Results

A small number of non-coding mutations generate de novo oncogenic edges in driver gene regulatory networks
We developed a new computational pipeline, called µ-cisTarget, to identify cis-regulatory mutations in a cancer sample, when both the whole genome sequence and the gene expression profile of that sample are available. The concept behind µ-cisTarget is to simultaneously identify "personalized" candidate master regulators for a given cancer sample, based on the gene expression profile of the sample (and optionally combined with a 'general' cancer gene signature of the same cancer subtype), and to prioritise SNVs and INDELs in the non-coding genome of the sample by their likelihood to generate de novo binding sites for any of these master regulators (Figure 1) . Among the list of candidates, we further determine a final set of mutations by applying two filters, namely: (i) the transcription factor for which a binding site is generated is itself expressed in the sample and is related to the cancer type; and (ii) the mutation is located close (up to 1 megabase (Mb)) to a target gene that is over-expressed, and within the same topologically associating domain (TAD) as the over-expressed target, it is related to the cancer type under study, and/or it is a potential driver gene (Figure 1 , see Methods). These criteria are largely inspired by previously published cis-regulatory driver mutations, such as those driving TERT, TAL1 and LMO1 [3] [4] [5] [6] : these oncogenes are over-expressed, and the generated binding sites are bound by (over-) expressed and cancer-type relevant transcription factors, namely GABPA for TERT and MYB for both TAL1 and LMO1.
To illustrate how µ-cisTarget works we first apply it to a simulated set of 67 variants spread around the TAL1 gene (up to 1 Mb upstream or downstream), where we inserted the true driver variant that generates a de novo MYB binding site. In the first step of the method, we used as input the top 500 MYB ChIP-seq peaks obtained in the same sample where the variant occurs (the JURKAT cell line), which finds the MYB and RUNX1 motifs as enriched ( Supplementary   Figure 1 ). This analysis thus infers a candidate network with MYB and RUNX1 as master regulators (Figure 2a ). Among the 68 variants, only one generates a new binding site for any of the enriched motifs, which is the true driver mutation, with a strong gain for the MYB motif (Figure 2b-c) . We then used the same master regulators to interrogate the recently discovered LMO1 enhancer mutation and again we could correctly predict MYB gain of motif as a result of this non-coding mutation (Figure 2b,d ).
Next, we tested whether µ-cisTarget could identify the well-known TERT promoter mutation from a sample with a fully sequenced genome (having the TERT mutation) and a matched transcriptome. The TERT promoter mutation results in a de novo ETS-binding site and occurs in 55% of melanoma samples [22] . We selected 7 melanoma samples from TCGA with a TERT promoter mutation and for which expression and whole genome mutation data is available through TCGA. We ask whether µ-cisTarget can identify the TERT promoter mutation in each individual sample as a candidate cis Gain-of-Function (cis-GoF) mutation, starting from the matched gene expression and mutation data. The first step consists of the identification of master regulators, starting from a gene signature of sample-specific up-regulated genes. For six out of the seven samples, µ-cisTarget predicts at least one ETS family member as master regulator (Supplementary Table 1 ). The second step of µ-cisTarget consists of identifying mutations that result in a gain-of-binding site near potential oncogenic drivers per sample (i.e. over-expressed genes that are either specific for the cell type or a potential driver gene, see Supplementary Table 2 ). In all those cases where an ETS factor is found as a master regulator, the TERT promoter mutations (both C228T and C229T) are predicted as gains of ETS binding sites (Figure   3a -c, Supplementary Table 1 ). Next, to test the specificity of our method we used wholegenome mutation calls for three of these melanoma samples and predicted candidate cis-GoF mutations (Figure 3b ). From the initial 110K to 240K mutations, µ-cisTarget identified 58 to 114 candidate cis-GoF mutations, including the TERT promoter mutations. All these candidates were either within introns or distal regulatory regions, while the TERT promoter mutations are among the few predictions located in a gene promoter (only TCGA-EE-A20H has two other candidate mutations that are located in a gene promoter) ( Supplementary Table 3 ). This demonstrates that µ-cisTarget is able to identify a manageable number of candidate functional non-coding mutations among thousands of candidates, while providing a prediction of their function in terms of samplespecific gene regulatory networks. More importantly, our results demonstrate that µ-cisTarget can identify a functional non-coding mutation (such as the TERT promoter mutation) in a samplecentric manner without requiring recurrence across a large cohort.
Application of µ-cisTarget to ten re-sequenced cancer cell lines
After validating µ-cisTarget on the TAL1, LMO1, and TERT mutations, we analysed ten widely used cancer cell lines as a discovery set ( Supplementary Table 4 ). We essentially implemented the same strategy as in the validation cases. Namely, we first identify cell-line specific master regulators that are relevant genes per cell line using motif enrichment analysis. Next, we identify 6 non-coding mutations in the genome of that cell line that create de novo binding sites for any of these master regulators, and that are near oncogenic drivers (relevant or driver genes (Supplementary Table 2 )). For the first step we obtained gene expression profiles of these cell lines from COSMIC Cell Lines Project [23] and predicted master regulators using gene signatures of these cell lines ( Table 1) . For each sample, all genes expressed with Z-score above 1 (compared to all other cell lines in Cosmic Cell Line Project) are used for motif-enrichment based master regulator discovery. The initial set of predicted transcription factors are filtered for their own over-expression (Z-score above 1) and their cancer type specificity (based on Supplementary Table 2 ). Interestingly, our motif-based predictions of master regulators is supported by ChIP-seq data (when available) for 6 / 33 master regulators across the 10 cell lines ( Supplementary Table 4 ).
Transcription factors identified at this step can be linked to several signalling pathways for the lung cancer line A549 [25] , KLF5 for the colon cancer line HT-29 [26] , and ETS-family transcription factors for prostate, colon, ovarian and breast cancer cell lines [27] [28] [29] [30] [31] . This class of transcription factors is expressed at an earlier developmental stage and is reactivated during tumorigenesis. Another group of transcription factors are the EMT associated factors: FOSL1 for MDA-MB-231 and DU-145, ZEB1 for SKOV-3, FOS for OVCAR-3, and SNAI2 for SK-MEL-5.
The majority of cell lines with these TFs as master regulators are derived from metastatic sites (SK-MEL-5, DU-145, PC-3). Of the remaining two cell lines, OVCAR-3 is derived from a chemo-resistant patient [32] and MDA-MB-231 demonstrates mesenchymal cell morphology [33] and is regarded as invasive in vitro [34] . Master regulators obtained at this step also corroborate well with what is known about these cell lines. For instance, the predicted master regulators for the lung cancer cell line A549 include NFE2L2 (NRF2) which is an essential gene for cell proliferation and chemoresistance in lung cancers, and specifically in A549 since knock-down of NFE2L2 in A549 inhibits proliferation [35] . Another example involves the MDA-MB-231 cell line for which ETS factors ETS1 and ETV1, as well as FOSL1 and STAT5A/B (the motif is directly annotated for both STAT5A and STAT5B) are found as master regulators. Gene knockdown studies involving these four transcription factors in this cell line demonstrated that each of these transcription factors are essential for growth, migration and metastatic potential of this cell line [36] [37] [38] [39] . And lastly, it has been shown for the ovarian cancer cell line SKOV-3 that inhibition of ZEB1, which is predicted as a master regulator, hampers migration in vivo and tumor growth in vitro when xenografted in mice [40] . In conclusion, master regulator predictions seem to capture and represent oncogenic processes ongoing in these cell lines.
Next, we obtained whole genome mutation calls for 10 cell lines by re-sequencing them using a combination of Illumina and Complete Genomics (CG) technology ( Supplementary Table 5 ).
On average the cell lines contain 1.69 Mio variants (SNVs and INDELS combined) of which, on average, 98% are non-coding ( Table 1 , Supplementary Table 5 ). For each sample, we scored non-coding mutations using sample-specific master regulators identified in the first step. Again, we defined candidate cis-GoF mutations as variants that generate de novo binding sites for any of the predicted master regulators, near oncogenic drivers. There is a high variation between the number of candidate cis-GoF mutations between cell lines and this correlates with the number of somatic coding mutations for these cell lines (r = 0.96 & p-value < 0.05 except for HCT-116) (Figure 4, Supplementary Figure 3) . Across all ten cell lines, µ-cisTarget initially identifies 485 candidate mutations, and even though we assign mutations to genes in a regulatory space up to 1
Mb, almost all of them results in an association covered within a TAD (468/485). We focus on those 468 mutations associated to their targets within a known TAD affecting 290 oncogenic drivers (Figure 4 , Supplementary Table 6 ). Only 29 genes have a protein altering mutation (i.e. missense substitution, in-frame or frameshift indel) that might be associated with its overexpression and none of these genes are affected by copy number aberrations, thus 94% of the genes are affected only by non-coding mutations ( Supplementary Table 7 ). Although there are no genomic positions recurrently mutated across the 10 cell lines, there are 24 genes that are recurrently affected by a cis-GoF mutation in 2 or more samples. For instance, FOXA1, which acts as pioneering factor in prostate cancer [41] , is found be affected by cis-GoF mutations in the prostate cancer cell lines DU-145, PC-3 and in the colon cancer cell line HT-29 ( Supplementary   Table 8 ). Moreover, there are two de novo master regulator -target gene pairs recurrent across may be possible that other binding site gains, located near genes that are not (yet) known as oncogenes for the cancer type under study, could play a role in the oncogenic program, we consider this as unlikely, given the large amounts of cancer type specific (and general) oncogenes that are known so far. In conclusion, µ-cisTarget provides a short list of candidate cis-regulatory mutations, that have a potential impact on the expression of relevant oncogenes.
Evaluation of predicted cis-regulatory mutations using matched epigenomes and allelespecific expression
Evaluating the potential impact of predicted oncogenic cis-mutations is challenging. Here, we test whether the predicted mutations may have an impact on the regulatory activity of the encompassing region. To this end, we use existing as well as newly obtained regulatory data, and allele specific expression information (as obtained from RNA-seq) for our 10 cell lines. Note that previous studies have used regulatory data to filter non-coding mutations [42] , but these were not sample-matched. Here we explicitly use matched regulatory data for the same sample.
Overlapping candidate cis-GoF mutations with sample matched H3K27Ac peaks revealed that 98 out of the 468 candidate mutations are in a potentially active regulatory region. For 6 out of the 10 cell lines, candidate cis-GoF mutations are enriched in active regulatory regions (hypergeometric test p-value <= 0.05, Figure 4, Supplementary Table 9 ). The same holds true for cis-GoF SNPs, since for all cell lines cis-GoF SNPs are enriched in active regulatory regions, indicating that µ-cisTarget can identify potentially functional variants, be it SNPs or mutations.
Additionally, we queried a large set of ChIP-seq peaks against other regulatory marks and transcriptions factors as obtained from the ChIP-Atlas database (http://chip-atlas.org) (433 datasets for 7 of our 10 cell lines, Supplementary Table 10 , see Methods) which revealed an additional 12 cis-GoF mutations that are located in a TF ChIP-seq peak in the corresponding sample ( Supplementary Table 6 ). In one of these examples, a predicted gain of a AP-1 binding site is observed upstream of the RARB gene in the breast cancer cell line MDA-MB-231, and this site co-localizes with a JUNB ChIP-seq peak (ChIP-seq performed in MDA-MB-231). Moreover, this mutation is indeed observed in the actual reads of the JUN ChIP-seq data so it strongly suggests that our prediction that this candidate mutation creates a de novo AP1 binding site ( Figure 5) .
Next, we investigated whether the predicted cis-regulatory mutations were present in an allelespecific manner in the expression data, in other words we checked if the mutation is associated to a gene with allele specific expression (ASE). Using coding heterozygous SNPs from WGS calls and RNA-seq data (which was not available for SKOV-3 and OVCAR-3) we identified genes with ASE, and this revealed that 154 of 468 candidate cis-GoF mutations show allelic bias in expression data (Supplementary Table 6 ). Note that our effort to identify mutations showing allelic bias in regulatory data failed since the coverage of H3K27Ac data was too low to determine variant allele frequency (80/98 candidate cis-GoF mutations in peaks have a depth of coverage below 5). When we expanded our search to also include SNPs, we identified 1304 SNPs 9 in H3K27Ac peaks with a motif gain for a master TF, and of these, 41 show allelic bias in the regulatory data ( Supplementary Table 11 ). This illustrates that gain of important motifs can yield allele-specific regulatory activity, but very few non-dbSNP, thus candidate somatic mutations were identified with this property across the 10 cell lines. On the other hand, by combining regulatory activity information and RNA-seq based ASE we found evidence of selection for 217 of 468 candidate cis-GoF mutations (Figure 4) . In conclusion, µ-cisTarget can be applied to matched genome-transcriptome data, or to matched genome-epigenome data, to obtain non-coding gain-of-function mutations resulting in gains of subtype-specific master regulators, near over-expressed oncogenes.
Discussion
Whole-genome re-sequencing of cancer genomes is taking a prominent place in research and the clinic. The identification and prioritization of candidate driver mutations in the non-coding genome is therefore a key challenge. Indeed, several recent studies indicate an important role for cis-regulatory mutations in disease, not only in cancer (e.g., TERT, TAL1 [3] [4] [5] ), but also in complex diseases (e.g., Type II Diabetes FTO locus [43] , Parkinson's disease [44] ) and in familial disorders (e.g. preaxial polydactyly [45] ). However, other studies have highlighted that cancer cis-regulatory mutations are usually not recurrent across patients, except for a few exceptions such as the TERT promoter mutation. To reconcile these two opposing directions, we decided to step away from recurrence calculations in a cohort, but to work under the assumption that cis-regulatory mutations may be rarer than expected. A consequence of this assumption, if each sample harbours none or only few cis-regulatory mutations, is that statistical enrichment analyses may fail to provide meaningful results. Rather, the identification of functional cisregulatory mutations may require a more ad hoc biological approach, which we explored in this study.
We are not the first to score and prioritize candidate mutations based on their putative gain (or loss) of transcription factor binding sites. In fact, most previously existing methods, such as FunSeq2, OncoCis, or RegulomeDB, use an ad hoc approach to annotate and filter candidate mutations based on motif loss/gain (FunSeq2, OncoCis) or on regulatory data from publicly available databases such as ENCODE (RegulomeDB). However, several important pieces of information are not utilized by previously existing tools, and are explored in our study. Firstly, the gain (or loss) of a motif is expected to be functionally relevant if the transcription factor itself is expressed in the cancer cells under study. If the transcription factor is (or was) not expressed, the gain of a binding site is not expected to be under positive selection.
Secondly, the motif gain (for an expressed transcription factor) should preferably represent a new binding site for a master regulator, meaning that this (over-expressed) transcription factor regulates other genes in the cancer cell through this motif. The approach we present here is to our knowledge the first one to take this criterion into account. Practically, to address this challenge we use a patient-specific, or subtype specific gene signature, in which over-represented motifs represent candidate motifs of master regulators.
Thirdly, the motif gain should yield either de novo regulatory activity of the encompassing enhancer, or should strengthen/amplify that enhancer. Such a gain of function may be visible as allele-specific bias of regulatory activity, whereby for example the ChIP-seq reads are homozygous for the variant.
Fourthly, the motif and enhancer gain should result in the up-regulation of a nearby oncogene, so that it provides a growth advantage to the cancer cell, and can be positively selected. Moreover, under this fourth piece of information, we expect that the predicted target gene is actually a known oncogene. Indeed, it is rather unlikely that previously unknown oncogenes could be discovered that are only up-regulated by a cis-regulatory mutation, and not by any other means (e.g., duplication, translocation, or mutation).
Our approach currently focuses on gain-of-function mutations that generate new binding sites for over-expressed activators, yielding up-regulation of a nearby oncogene. Clearly, several other scenarios are not covered by our proof-of-concept analyses. These include for example: the loss of an activator binding site near a tumour suppressor (e.g., loss of p53 binding site); the loss of a repressor binding site near an oncogene; or the gain of a repressor binding site near a tumour suppressor. We have focused in this study on the gain of an activator site near an oncogene because the currently known cis-regulatory driver mutations are all of this class, and this is the most conceivable and most pragmatic way to work within the context of motif discovery and gene regulatory networks. Future work is needed to address the other categories, and may reveal new types of cis-regulatory mutations. Another possible increase of sensitivity would be to also allow motif gains for relevant transcription factors that are expressed in the sample, and related to the cancer type, but for which the motif was not enriched in the input gene signature.
Our method provides a handle on understanding non-coding mutations in the context of regulatory genomics, thus we envisioned µ-cisTarget not as a method for a final analysis but rather a starting point for in depth analysis. The typical use of a strategy like we depict here can be either to annotate a cancer genome with functional information regarding cis-regulatory mutations; or in a research context to generate a list of candidate mutations that can be further tested in a targeted screen, for example using massively parallel enhancer-reporter assays or CRISPR-Cas9 based modulation/mutation of the candidate mutations.
In conclusion, we present a computational framework inspired by a cancer biological viewpoint on oncogenic driver mutations. Our method can be used to identify candidate cis-regulatory mutations using sequence information alone, but works best on samples with combined genome and transcriptome data; while optimal results can be obtained if also matching epigenome data is available. Overall our results suggest the presence of only few cis-regulatory driver mutations per genome in cancer genomes that may alter the expression levels of specific oncogenes.
Materials and methods
Analysis of melanoma whole genomes for TERT promoter mutations
Expression data (Z-scores across all TCGA sequenced cancers) for seven melanoma samples (Supplementary Table 1) with TERT promoter mutations based on [22] were downloaded from Cosmic (v74). The signatures per sample (i.e. genes that have an expression Z-score above 1) were analysed by iRegulon to build the personalized gene regulatory networks (using the following parameters: motif collection 19K, putative regulatory region centered around TSS [20kb, 10kb, 500bp], motif rankings database across 10 and 7 species, NES threshold=3, ROC=0.03, rank threshold=5000).
Raw sequence data (bam files) for six melanoma samples was downloaded from GDC Data Portal (Legacy Archieve) and re-analyzed with VarScan [46] (command somatic with minimum variant allele frequency of 0.1, and a minimum coverage of 5 and 2 reads in tumor and normal samples, respectively). Non-coding mutations associated to melanoma-related or cancer driver genes were scored with MotifLocator for master TFs obtained in the previous step. The list of candidate cis-GoF mutations was filtered further using topologically associating domains (TADs) from 21 human cell lines and tissues [47] . intersected for samples that were sequenced with both technologies. Coding variants were subtracted using protein coding exon locations from GENCODE (v19). Variants were annotated as non-SNPs or SNPs using dbSNP build 144 [48] .
Whole
Cell line specific regulatory data
H3K27ac ChIP-seq data for 6/10 cell lines were obtained from GEO and literature: A549 and HCT-116 (GSE31755) [49] , HT-29 (GSE53602), PC-3 [50] , MDA-MB-231 [51] , SK-MEL-5 (GSE60666) [52] . For the remaining 4 cell lines (OVCAR-3, SKOV-3, DU-145, Colo-205), ChIP-seq was performed in this study. The cell lines were grown to ~85% confluence per 15-cm dish. A total of 20 million cells per sample were collected, yielding ~20 fractions of chromatin.
ChIP samples were prepared following the Magna ChIP-Seq preparation kit using at least two chromatin fractions and 2-2.5 µg of antibody per fraction. Anti-histone H3 acetyl K27 antibody (ab4729, Abcam) antibody was used for ChIP. Per sample, 5-30 ng of precipitated DNA or input was used to perform library preparation according to the Illumina TruSeq DNA Sample preparation guide. In brief, the immunoprecipitated DNA was end-repaired, A-tailed and ligated to diluted sequencing adapters (1/100). After PCR amplification (15-18 cycles) and bead purification (Agencourt AmpureXp, Analis), the libraries with fragment size of 300-500 bp were sequenced using the HiSeq 2000 (Illumina). Sequence reads were mapped to the reference genome (hg19-Gencode v18) using Bowtie2 2.1.0 and narrow peaks were called using MACS2 algorithm (q-value < 0.001) [53] . Then the peaks less than 350 bp from each other were merged. Additionally, we have used peak calls from ChIP-Atlas database for 433 regulatory datasets (TF and chromatin ChIP-seq) across 7 cell lines ( Supplementary Table 10 , http://chip-atlas.org).
Selection of cancer type specific TFs and TGs
Lists of cancer-type specific genes were extracted from NCBI Gene database (http://www.ncbi.nlm.nih.gov/gene) ( Supplementary Table 2 ). Next, a collection of 1050 known cancer driver genes compiled from different resources [54] [55] [56] [57] [58] [59] was used to further annotate the cancer type related genes (Supplementary Table 2 ).
Cell line specific gene signatures and identification of sample-specific master regulators
Gene expression data (Z-scores) per cell line was obtained from Cosmic Cell Lines project (http://cancer.sanger.ac.uk/cell_lines). Cell line specific gene sets were created by selecting genes that have an expression Z-score above 1. The signatures were analysed by iRegulon to build the personalized gene regulatory networks (using the following parameters: motif collection 19K, putative regulatory region centered around TSS [20kb, 10kb, 500bp], motif rankings database across 10 and 7 species, NES threshold=3, ROC=0.03, rank threshold=5000). TFs that are cancer type related and expressed in the cell line (Z-score above 1) were considered as master regulators of the corresponding cell line ( Table 1) .
Detection of candidate mutations
The non-coding mutations were assigned to genes using GREAT tool (up to 1 Mb) [60] . Only the non-coding mutations associated with genes that are a) over-expressed in the cell line (expression Z-score above 1), b) relevant to the cancer type or on the list of known cancer drivers were scored by MotifLocator [13] .
All the motifs corresponding to master TFs from the personalized gene regulatory networks were tested to reveal if any mutation from the matched cell line cause a gain of any of these motifs.
Annotation of mutations using topologically associating domains (TADs)
The assignment of the mutations to the potential target genes within the space 1 Mb is further annotated using a large dataset of TAD boundaries generated for 21 samples (14 human tissues and 7 human cell lines) [47] . In the output file, the information whether the mutation and the gene fall between the boundaries of the certain sample is provided, i.e. if the mutation is in the same TAD region with the promoter of the gene. This annotation can be used to further filter mutationto-genes associations.
Genome-wide screening of DNA sequences by MotifLocator
A collection of 8053 unique PWMs directly annotated to 1628 TFs was used for scoring with MotifLocator [13] . Scoring was performed at the mutation sites with a window size between 20 bp to 60 bp depending on the motif size (20 bp if the motif size is 15 bp or less, 30 bp if motif size is between 16 bp and 25 bp, and 60 bp if the motif size is larger than 25 bp). The variants with mutant MotifLocator score >= 0.90 and delta >= 0.1 were selected (where delta represents the difference between MotifLocator scores of mutant and wild type sequences).
Validation of candidate mutations using matched transcriptome and epigenome data
RNA-seq data (bam files) was downloaded for 8 (A549, COLO-205, DU-145, HCT-116, HT-29, MDA-MB-231, PC-3, SK-MEL-5) cell lines from GDC Data Portal (Legacy Archieve).
Heterozygous SNPs per cell line were obtained from whole genome mutation calls by requiring at least 5 reads for reference and variant allele, as well as requiring at least 0.10 VAF. Heterozygous SNPs were intersected for samples that were sequenced with both Illumina and Complete Genomics. Allele specific expression per cell line was calculated using MBASED one-sample analysis [61] . Any gene with an adjusted p-value ≤ 0.05 and estimated MAF ≥ 0.6 was annotated as exhibiting allele-specific expression.
Availability
The data generated for this study (H3K27ac ChIP-seq for OVCAR-3, SKOV-3, DU-145, COLO-205) will be deposited in NCBI's Gene Expression Omnibus. Genome data are being deposited at the European Genome-phenome Archive (EGA, http://www.ebi.ac.uk/ega/) which is hosted at the EBI. The code for µ-cisTarget is freely available at https://github.com/aertslab/mucistarget and a web-implementation is available at http://mucistarget.aertslab.org. All the represented TGs are over-expressed in MDA-MB-231, are associated with breast cancer and are known cancer drivers. b) A cis-GoF mutation in a distal enhancer (590Kb upstream) of RARB gene creates a de novo AP1 binding site (resulting in a red edge between AP1 family transcription factor FOSL1 and RARB). c) IGV screenshot shows that the mutation is
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